LCL161

For research use only. Not for use in humans.

目录号:S7009

LCL161 Chemical Structure

CAS No. 1005342-46-0

LCL-161, 一种second mitochondrial activator of caspase (SMAC, 线粒体促凋亡蛋白)模拟物, 能有效地结合并抑制多种IAPs(i.e. XIAP, c-IAP)。

规格 价格 库存 购买数量  
RMB 1194.96 现货
RMB 3883.15 现货
RMB 8176.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的LCL161发表文献23篇:

产品安全说明书

IAP抑制剂选择性比较

生物活性

产品描述 LCL-161, 一种second mitochondrial activator of caspase (SMAC, 线粒体促凋亡蛋白)模拟物, 能有效地结合并抑制多种IAPs(i.e. XIAP, c-IAP)。
靶点
cIAP [1] XIAP [1]
体外研究

LCL161以高亲和力与凋亡抑制蛋白因子(IAPs)结合,并启动对cIAP1和cIAP2的破坏,其通过胱天蛋白酶的激活进一步诱导细胞凋亡。LCL161单独给药时适度抑制表达FLT3-ITD的细胞生长,IC50的范围为~0.5 μM (Ba/F3-FLT3-ITD 细胞)到~4 μM (MOLM13-luc+ 细胞)。观察到的LCL161抗D835Y突变体的效力相当高,测试抗Ba/F3-D835Y细胞时,IC50为~50 nM。LCL161 与PKC412结合治疗MOLM13-luc+细胞比其任何一个药剂单独使用具有更显著的细胞杀伤力,Calcusyn复合指数表明其具有协同作用。 PKC412和LCL161诱导MOLM13-luc+细胞的凋亡。PKC412 和 LCL161结合比其单独使用能够导致更高的细胞凋亡率。LCL161通过与PKC412阳性结合,抑制基质介导的表达FLT3的突变细胞的存活。LCL161抑制Ba/F3.p210细胞的生长,IC50为~100 nM。LCL161与ABL抑制剂,伊马替尼结合,能够协同抗BCR-ABL表达的细胞。对于在靶蛋白表达点突变的耐药细胞,LCL161也具有抵抗活性。1000 nM的LCL161能够大部分或完全杀死耐PKC412的Ba/F3衍生的细胞系,其在FLT3的ATP结合囊表达含有点突变的FLT3-ITD。100到1000 nM浓度的LCL161也表现出抗Ba/F3细胞的活性, Ba/F3细胞能够表达各种伊马替尼和尼罗替尼耐药的BCR-ABL点突变。[1] 对LCL161抗23细胞系的评估,通过儿科临床前测试计划(PPTP)在体外进行96小时。对23种测试PPTP细胞系中的其中3种,10 μM浓度下的LCL161能够抑制50%的生长。3种细胞系包括2种T细胞ALL细胞系(COG-LL-317和CCRF-CEM),以及间变性大细胞淋巴瘤细胞系(Karpas-299),CCRF-CEM和Karpas-299表现出较低的相对IC50值(分别为0.25和1.6 μM)。[2] LCL161对人体免疫亚群表现出免疫调节性能。用LCL161处理T淋巴细胞显著增强具有激活作用的细胞因子分泌,对 CD4和CD8 T细胞生存或分化的作用很小。LCL161处理外周血单核细胞,在体外合成多肽存在下,显著增强初始T细胞的启动。髓样树突状细胞在LCL161作用下表型成熟,表明降低了基于肿瘤抗原对抗疫苗的能力。这些作用可能通过观察到的典型和非典型NF-κB途径的激活介导,伴随LCL161导致抗凋亡分子上调。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LOX M2PlRWZ2dmO2aX;uJIF{e2G7 NH\Jb5EyODBibXevb4c> NGP5WXI5KGi{cx?= NUHnR5l5WG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[0mDUEGg[IVoemGmYYTpc44hcW5iaIXtZY4hVE:[IHPlcIx{KHinbn;ndoFnfGWmIHnuJI1wfXOnIHH0JFExOCCvZz;r[{wheG9iYX\0[ZIhQCCqcoOgZpkhX2W|dHXyckBjdG:2dHnu[{BidmGueYPpdy=> NF\2bWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
LOX M{jEPWZ2dmO2aX;uJIF{e2G7 NFPHSXg5KGi{cx?= MXzQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjZZNx[XOnIEOvO{Bi[3SrdnH0bY9vKGmwIHj1cYFvKEyRWDDj[YxteyC6ZX7v[5Ji\nSnZDDpckBud3W|ZTDh[pRmeiB6IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[Xl? NE\Odpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
MDA-MB-231 NFjXWmZHfW6ldHnvckBie3OjeR?= MUmyMlUhfG9iMUCgeW0> NGnHbXkyQSCqcoO= MmnCRolv\GmwZzDh[oZqdmm2eTD0c{BkUUGSMTDCTXI{KGSxbXHpckBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIGTOSoFteGijIHzleoVtKGG2IEKuOUB1dyBzMDD1UUBi\nSncjCxPUBpenNiYomgSWxKW0F? NIHQenY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
BxPC3 NIizT|RHfW6ldHnvckBie3OjeR?= NIXkbXI{NjNidV2= NXLHeHBuPSCmYYnz NELoTWJRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDgFCFMzDj[YxteyCjdDCzMlMhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? NH76fXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
HCT15 NH;ncVFHfW6ldHnvckBie3OjeR?= NULwd|hKOy5|IIXN MXq1JIRigXN? MX;Qc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> M{T2clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
SW620 MmLoSpVv[3Srb36gZZN{[Xl? NH7IclkyNjFidV2= M2TqRlUh\GG7cx?= NX\jNohLWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1d4MkCgZ4VtdHNiYYSgNU4yKHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? NIXVbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
SW620 NIHXcG5HfW6ldHnvckBie3OjeR?= Mn25N{4{KHWP MlnUOUBl[Xm| MkO1VI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3c3OjBiY3XscJMh[XRiMz6zJJVOKGGodHXyJFUh\GG7czDifUBOXFNiYYPzZZk> M375SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
LOX NF;oWndHfW6ldHnvckBie3OjeR?= Mkj1N{4{KHWP MoKzN{Bl[Xm| M33MbXBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxQYCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgN{Bl[Xm|IHL5JG1VWyCjc4PhfS=> NHnSR209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
LS180 NWDwTnlrTnWwY4Tpc44h[XO|YYm= M1GyUFMvOyC3TR?= NG\m[4I2KGSjeYO= NFLwTIlRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNWzF6MDDj[YxteyCjdDCzMlMhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
H460 NWnwOVJKTnWwY4Tpc44h[XO|YYm= Mn3TN{4{KHWP M{\WflUh\GG7cx?= Mm\qVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> NYXVU3VnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
LOX NVfNeFRoTnWwY4Tpc44h[XO|YYm= MWixNFAhdWdxa3e= MV24JIhzew>? MV\QcIF{dWFiY3;uZ4VvfHKjdHnvckBqdiCwdXTlJI1wfXOnIIjlco9oemGodHXkJJdqfGhiaIXtZY4hVE:[IHPlcIx{KGG2IEGwNEBu\y:tZzygdI8hdWWjc4Xy[YQh[XRiODDodpMtKEOyIE2gN{4{KM7:TT6= MkDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
SW620 NVfUb5hwTnWwY4Tpc44h[XO|YYm= NGG5bVI2KGSjeYO= M1;HUGlv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJI9nKGi3bXHuJHNYPjJyIHPlcIx{KHSxIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDNWHMh[XO|YYmsJGVEQTBiPTC2MlY3KM7:TT6= M{HibFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
LOX MWnGeY5kfGmxbjDhd5NigQ>? NEfuNHkyODBibXevb4c> NYnmRXlHQCCqcoO= NXex[Y9UTHK3ZzD1dJRic2ViaX6geJVud3Jib3[gcpVl\SCvb4Xz[UB5\W6xZ4Lh[pRm\CC5aYToJIh2dWGwIFzPXEBk\WyuczDheEAyODBibXevb4ctKHCxIH3lZZN2emWmIHH0JFghcHK|LDDEdpVoKHWydHHr[UA:KDF6LkSg{txONg>? NHnpRYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
SW620 MkTrSpVv[3Srb36gZZN{[Xl? M1zBdVIvPSC3TR?= MW[1JIRigXN? M{XqTmlv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJI9nKGi3bXHuJHNYPjJyIHPlcIx{KHSxIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgUXRUKGG|c3H5 NIfqOWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
LOX M{fnRmZ2dmO2aX;uJIF{e2G7 MV:xNFAhdWdxa3e= MnfXPEBpenN? NHP0OIRKdiC4aY\vJIlvcGmkaYTpc44hd2ZiWFnBVEBDUVJ{IHTvcYFqdiCrbjDoeY1idiCOT2igZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjZZNx[XOnIEOvO{Bi[3Srdnn0fUBifCBzMECgcYcwc2duIIDvJIFnfGW{IEigbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MljTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
LOX NFXUXpBHfW6ldHnvckBie3OjeR?= MnHaNVAxKG2pL3vn NX33RZp6QCCqcoO= M4npRWlvKH[rdn:gbY5pcWKrdHnvckBw\iC[SVHQJGJKWjJiZH;tZYlvKGmwIHj1cYFvKEyRWDDj[YxteyC6ZX7v[5Ji\nSnZDDpckBvfWSnIH3veZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJINie3Cjc3WgN{84KGGldHn2bZR6KGG2IEGwNEBu\y:tZzygdI8h[W[2ZYKgPEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NV3mRXQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
MDA-MB-231 NW\JcFZDTnWwY4Tpc44h[XO|YYm= NGDId|QxNjN5IITvJFMvOyC3TR?= M1LQc|E6KGi{cx?= NVTBflJ5UW6qaXLpeIlwdiCxZjDjTWFROS9{IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKFSQRnHsdIhiKGyndnXsJIF1KDBwM{egeI8hOy5|IIXNJIFnfGW{IEG5JIhzeyCkeTDFUGlUSQ>? NEm1OXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
CHL1 NFHYNIZHfW6ldHnvckBie3OjeR?= MoOyNE41KHSxIEGwJJVO MXiyPEBpenN? M1PTfWlvcGmkaYTpc44hd2ZiY1nBVFEhcW5iaIXtZY4hS0iOMTDj[YxteyCjdDCwMlQhfG9iMUCgeW0h[W[2ZYKgNlghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NWnBcXFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
SKMES1 NGDRR2hHfW6ldHnvckBie3OjeR?= M{n0dFIvPSC3TR?= MYW1JIRigXN? MVzQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDhdI9xfG:|aYOgbY4hcHWvYX6gV2tOTVNzIHPlcIx{KGG2IEKuOUB2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 MojCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
Capan1 NGP3[YFHfW6ldHnvckBie3OjeR?= NU\PenoyOi53IIXN MUC1JIRigXN? Mn7tVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIlvKGi3bXHuJGNieGGwMTDj[YxteyCjdDCyMlUhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? NH:2eVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
AGS MYXGeY5kfGmxbjDhd5NigQ>? M3TqNFIvPSC3TR?= M1PaOlUh\GG7cx?= MVrJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDBS3Mh[2WubIOgeI8h[2:wYYT1cZVu[WJvaX7keYNm\CCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? NILjRVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
U118MG NVfEXZZoTnWwY4Tpc44h[XO|YYm= MWKyMlUhfU1? NEDyWHg2KGSjeYO= MV7Qc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDhdI9xfG:|aYOgbY4hcHWvYX6gWVEyQE2JIHPlcIx{KGG2IEKuOUB2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
PC3 NF7LeYpHfW6ldHnvckBie3OjeR?= NXLDdFV5Oi53IIXN MV21JIRigXN? NYfjU5hbUW6mdXP0bY9vKG:oIIPlcpNqfGm8YYTpc44hd2ZiaIXtZY4hWEN|IHPlcIx{KHSxIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIF1KDJwNTD1UUBi\nSncjC1JIRigXNiYomgUXRUKGG|c3H5 MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
CCRF-CEM MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tR2VOKGOnbHzzMEBIUTVyIE2gNE4zPSEQvF2u NVnFRZR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|U2OjZpPkK4OFM2PTJ4PD;hQi=>
MDA-MB-231 M3HWPWZ2dmO2aX;uJIF{e2G7 MYGyJIhzew>? M3fDcWlv\HWldHnvckBw\iClSVHQNUBl\We{YXTheIlwdiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFIhcHK|LDDFR|UxKD1iMD6wNFA1KM7:TT6= M{fBelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEmyN|E4Lz5{OES5NlMyPzxxYU6=
MDA-MB-231 MYnDfZRwfG:6aXPpeJkh[XO|YYm= NULXXVFUPzJiaILz M4XDO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiRVO1NEA:KDBwMEC3PEDPxE1w M1u0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEmyN|E4Lz5{OES5NlMyPzxxYU6=
HEK293 M1Xmb2Z2dmO2aX;uJIF{e2G7 NHrKZ4YzKGi{cx?= NX;GWodCUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBHVEGJLYTh[4dm\CC[SVHQJEh2dmuwb4fuJI9zcWerbjmgbY51\XKjY4Tpc44hf2m2aDDmeYxtKGynbnf0bEB2dnSjZ3fl[EBk[XOyYYPlMVkh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bi\nSncjCyJIhzeyCkeTDpcY12dm:ycnXjbZBqfGG2aX;uJIF{e2G7LDDFR|UxKD1iMD6wN|Uh|ryPLh?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR7MkOxO{c,Ojh2OUKzNVc9N2F-
MDA-MB-231 NH3GXXBCdnSrdIXtc5Ih[XO|YYm= MkC3N|AhdWdxa3e= M1TXeFI1KGSjeYO= NHjJfmhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIjlco9oemGodHXkJIlvKEKjbHKvZ{BUS0mGIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKGe{b4f0bEBqdmirYnn0bY9vKGG2IEOwJI1oN2upIHHkcYlvcXO2ZYLl[EB3cWFib4LhcEBo[X[jZ3Wg[o9zKDJ2IHThfZM> MmmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUKzNVcoRjJ6NEmyN|E4RC:jPh?=
MDA-MB-231 NXfndlJITnWwY4Tpc44h[XO|YYm= NHOweFMzKGi{cx?= MULJcoR2[3Srb36gc4YhcW62cnHj[YxtfWyjcjDjTWFROSCmZXfyZYRifGmxbjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDJiaILzMEBKSzVyIE2gNE4xODB2IN88UU4> NHvpOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5NVYxOCd-M{CwPVE3ODB:L3G+
MDA-MB-231 M3zFbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NIi1ZmU4OiCqcoO= MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNE4xODd6IN88UU4> MkS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUG2NFAoRjNyMEmxOlAxRC:jPh?=
HEK293 M3O4V2Z2dmO2aX;uJIF{e2G7 NX6xRVU4OiCqcoO= NGPHfmdKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGZNSUdvdHHn[4VlKFiLQWCgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB4cXSqIH\1cIwhdGWwZ4ToJJVvfGGpZ3XkJINie3Cjc3WtPUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[XluIFnDOVAhRSByLkCzOUDPxE1w MlXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUG2NFAoRjNyMEmxOlAxRC:jPh?=
SKOV3 NWrhc|dWSXCxcITvd4l{KGG|c3H5 NFn3eHY1QCCqcoO= MlrPTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBi\nSncjC0PEBpenNiYomgTY5kfUO7dHWgV|MhdGm4ZT3j[YxtKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMEGg{txONg>? MnvBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyOUWzPFYoRjNzMEm1N|g3RC:jPh?=
SKOV3 NUTpTFlnSXCxcITvd4l{KGG|c3H5 MnnLNlQhcHK| M{jKbWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iU1vPWlMh[2WubIOgZZN{\XO|ZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W[2ZYKgNlQhcHK|IHL5JGlv[3WFeYTlJHM{KGyrdnWtZ4VtdCCjbnHsfZNqeyxiRVO1NEA:KDBwMECzJO69VS5? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB7NUO4Okc,OzFyOUWzPFY9N2F-
BL21(DE3) MXXGeY5kfGmxbjDhd5NigQ>? NUXuXmVmOiCqcoO= NYDCV3dQTGm|cHzhZ4Vu\W62IH;mJIJqd3SrbonsZZRm\CCDVmDGJIZzd21iTj30[ZJucW6jbDDIbZMhfGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHhKSVBvQlnSN{Bld22jaX6gLFI2OyC2bzCzOFchemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV|KTDj[YxteyCrbnP1ZoF1\WRiZn;yJFIhcHK|IHL5JGRGVE[LQTygTWM2OCB;IECuNFQ5KM7:TT6= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB7NUO4Okc,OzFyOUWzPFY9N2F-
BL21(DE3) M{e3fmZ2dmO2aX;uJIF{e2G7 M{fxeVghcHK| NIPVRmhFcXOybHHj[Y1mdnRib3[gZolwfGmweXzheIVlKEGYUF[g[pJwdSCQLYTldo1qdmGuIFjpd{B1[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gXGlCWC2ESWKzJIRwdWGrbjCoNlU{KHSxIEO0O{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KGmwY4XiZZRm\CCob4KgPEBpenNiYomgSGVNTkmDLDDJR|UxKD1iMD6wOVMh|ryPLh?= M2nZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
A549 M1rxR2Z2dmO2aX;uJIF{e2G7 Mn;kNUB2VQ>? NGW5N40{KGi{cx?= MY\JcoR2[3Srb36gc4Yh[0mDUEKg[IVoemGmYYTpc44hcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[0mDUEKgdJJwfGWrbjDs[ZZmdCCjdDCxJJVOKGmwY4XiZZRm\CCob4KgN{BpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV3MEG1OUc,OzF3NUCxOVU9N2F-
SK-MEL-28 NYi0W|h1TnWwY4Tpc44h[XO|YYm= NHnKU4cyKHWP NVHJUpNPOyCqcoO= NH\m[2VKdmS3Y4Tpc44hd2ZiY1nBVFEh\GWpcnHkZZRqd25iaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBkUUGSMTDwdo91\WmwIHzleoVtKGG2IEGgeW0hcW6ldXLheIVlKG[xcjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M1zZSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUWwNVU2Lz5|MUW1NFE2PTxxYU6=
SK-MEL-28 MUDGeY5kfGmxbjDhd5NigQ>? M{TmSVEhfU1? MUezJIhzew>? NV;pT5R5UW6mdXP0bY9vKG:oIHPJRXAzKGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[0mDUEKgdJJwfGWrbjDs[ZZmdCCjdDCxJJVOKGmwY4XiZZRm\CCob4KgN{BpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NUfxc4NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVAyPTVpPkOxOVUxOTV3PD;hQi=>
HEK293T NVrZU2NsTnWwY4Tpc44h[XO|YYm= NH3CUZcyOCC3TR?= NGDlWZM3KGi{cx?= MULDc5ZidGWwdDDibY5lcW6pIHHm[olvcXS7IITvJGhCNUKLUkOg[I9u[WmwIH;mJHhKSVBiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBj[W6mIHnueIVve2m2eTDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NVXkTWhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVAyPTVpPkOxOVUxOTV3PD;hQi=>
A549 MnfKSpVv[3Srb36gZZN{[Xl? NIPJU24yKHWP NHu1NYE{KGi{cx?= MoW1TY5lfWO2aX;uJI9nKGOLQWCxJIRm\3KjZHH0bY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOLQWCxJJBzd3SnaX6gcIV3\WxiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFMhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NWqxd2lyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVAyPTVpPkOxOVUxOTV3PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / surivivin ; 

PubMed: 27737687     


A549 and H460 cells were treated for 48 h with 0-20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting. β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
Growth inhibition assay
Cell viability; 

PubMed: 27737687     


Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
体内研究 LCL161显著增强PKC412抑制Ba/F3-FLT3-ITD-luc+细胞体内生长的能力。LCL161能够与标准化疗剂,阿糖胞苷和阿霉素阳性结合,抗FLT3-ITD表达细胞和D835Y表达细胞。Nilotinib与LCL161结合能够实现抑制白血病生长的累加作用。LCL161 (100 毫克/千克)增强高适度剂量nilotinib (100毫克/千克)对患有白血病小鼠的体内作用。[1] 通过儿科临床前测试程序(PPTP)测试CL161(口服给药,一周两次)在体内(30 或 75 毫克/千克[实体瘤] 或100 毫克/千克 [ALL])的作用。LCL161诱导显著的EFS在大约三分之一实体瘤异种移植物(osteosarcoma and glioblastoma) 中的分布差异,但不影响ALL异种移植物中的情况。没有观察到可评价客观疗效者。在体内,LCL161对儿科临床前模型研究表现出有限的单剂量活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: 人 T 细胞 ALL 细胞系 COG-LL-317
  • Concentrations: ~10 μM
  • Incubation Time: 96小时
  • Method:

    使用DIMSCAN进行体外测试


    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (199.74 mM)
Water Insoluble
Ethanol '20 mg/mL warmed

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 500.63
化学式

C26H33FN4O3S

CAS号 1005342-46-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03111992 Completed Drug: PDR001|Drug: CJM112|Drug: LCL161 Multiple Myeloma Novartis Pharmaceuticals|Novartis December 18 2017 Phase 1
NCT01934634 Unknown status Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel Metastatic Pancreatic Cancer US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC March 2014 Phase 1
NCT01968915 Completed Drug: LCL161|Drug: Paclitaxel Neoplasms Novartis Pharmaceuticals|Novartis November 2013 Phase 1
NCT01617668 Completed Drug: LCL161|Drug: paclitaxel Breast Cancer Novartis Pharmaceuticals|Novartis August 2012 Phase 2
NCT01240655 Completed Drug: LCL161|Drug: Paclitaxel Solid Tumors Novartis Pharmaceuticals|Novartis April 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

IAP Signaling Pathway Map

Tags: 购买LCL161 | LCL161供应商 | 采购LCL161 | LCL161价格 | LCL161生产 | 订购LCL161 | LCL161代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID